EXPLORE THE SCIENCE
TL;DR: A 2026 systematic review and meta-analysis in Brain, Behavior, & Immunity – Health found that adding celecoxib to antidepressants was linked to lower depressive symptom scores in 7 small trials, but the efficacy evidence was rated very low certainty. Ke…
Read article
TL;DR: A 2026 review in Translational Psychiatry argues for a biologically meaningful inflammatory depression subgroup, with CRP, IL-6, TNF-alpha, glial activation, kynurenine metabolism, and synaptic plasticity linking immune signaling to symptoms and treatme…
Read article
TL;DR: A 2026 methodology paper in European Archives of Psychiatry and Clinical Neuroscience describes EMBER-MDD, a research-only multi-omic study designed to find treatment-resistance and esketamine-response biomarkers in about 420 adults with major depressiv…
Read article
TL;DR: A 2026 study in Behavior Genetics found that combining major depressive disorder and alcohol use disorder polygenic scores improved prediction of their comorbidity in 7,965 Add Health participants, but added little for either condition alone. Key Findin…
Read article
TL;DR: A 2026 preprint in medRxiv found that treatment-resistant depression affected 34% of medication-exposed major-depression patients in Pakistan’s DIVERGE study, with social support and CYP2C19 metabolizer status standing out as locally important treatment…
Read article
TL;DR: A 2026 preprint in medRxiv linked recurrent major depression to direction-specific effective-connectivity changes, with strongest patterns in cerebellar-cortical, sensorimotor, cognitive, neurotransmitter, and oligodendrocyte precursor cell maps. Key Fi…
Read article
TL;DR: A 2026 review in Neuropsychiatric Disease and Treatment argues that miR-425-3p is a candidate depression biomarker because it connects stress biology, MAPK/Wnt signaling, inflammation, and antidepressant response evidence. Key Findings 280 million MDD b…
Read article
TL;DR: A 2026 study in Interactive Journal of Medical Research used structured hospital records plus natural language processing of clinical notes to profile major depressive disorder in Belgium, finding that 46% of 1,147 adults met a real-world treatment-resi…
Read article
TL;DR: A 2026 randomized study in The British Journal of Psychiatry found that the experimental 5-HT4 receptor agonist PF-04995274 did not mimic citalopram’s early emotional-bias effects in unmedicated depression, but it was linked with lower depression rating…
Read article
TL;DR: A 2026 systematic review in Molecular Psychiatry found that microglia-related findings across major depression, bipolar disorder, and schizophrenia were better explained by biological subgroups than by one uniform diagnosis-by-diagnosis inflammation pat…
Read article